Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Return on Net Investment (RONI) for the year ending December 31, 2023

Agios Pharm Return on Net Investment (RONI) is NA for the year ending December 31, 2023. Return on net investment measures the profitability of a company relative to its net investment, which includes total investments minus short-term investments and long-term debt. It is calculated by dividing the net income by the net investment. This ratio provides insights into the return generated for each unit of net investment made by the company. A higher return on net investment indicates better profitability and efficient utilization of the company's invested capital.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends